Investor Area

News

Announcements by type

  • Presentation

  • Corporate

  • Newsletter

  • Regulatory

  • Financial

  • Clinical

  • Reset

 

CLINUVEL PHARMACEUTICALS LTD today informed its shareholders and interested investors that Jefferies Australia Pty Ltd has initiated independent analyst coverage on the Company. […] Download PDF

Download PDF
 
 

The Value in the Vines Investor Conference Presentation is available to download.

Download PDF
 
 

  Appendix 4G and Corporate Governance Statement is available to download.

Download PDF
 
 
Friday, 09 October 2020

CLINUVEL Annual Report 2020

CLINUVEL’s Annual Report for the year ended 30 June 2020 is available to download here.

Download PDF
 
 
Friday, 09 October 2020

CLINUVEL Annual General Meeting 2020

CLINUVEL PHARMACEUTICALS LTD’s 2020 Annual General Meeting (AGM) will be held on Wednesday, 11 November 2020 at 06.00pm (Melbourne time). To comply with COVID19 requirements set out in Government restrictions on travel and public gatherings, the AGM will be held as a virtual meeting. The Company will rely on technology to facilitate shareholder engagement during […]

Download PDF
 
 
Wednesday, 07 October 2020

SCIENTIFIC COMMUNIQUÉ VI

Despite government campaigns to curb increases, current statistics show the rate of skin cancer is escalating, particularly in regions with predominantly fair-skinned populations. Skin cancer diagnoses have increased considerably over the last five decades, at a rate of 4% per annum. Approximately 5.3 million individuals are diagnosed with a skin cancer in the USA annually. […]

Download PDF
 
 
Tuesday, 06 October 2020

CLINUVEL News & Facts site live

Earlier this week CLINUVEL launched a new microsite, CLINUVEL News & Facts. The CLINUVEL News & Facts site gives an opportunity to explore and discuss the people, science and ideas that underpin CLINUVEL. Read more about the concept here.

Download PDF
 
 
Monday, 28 September 2020

Kommuniqué V, 2020

Kommuniqué V, 2020

Download PDF
 
 
Wednesday, 23 September 2020

CLINUVEL Newsletter V

CLINUVEL Newsletter V, 2020

Download PDF
 
 
Wednesday, 23 September 2020

CLINUVEL Confirms AGM Date

CLINUVEL Confirms AGM Date

Download PDF
 
 
Wednesday, 16 September 2020

Change of Director’s Interest Notice

Appendix 3Y – Change of Director’s Interest Notice is available to download as PDF

Download PDF
 
 

First patient dosed in SCENESSE® DNA Repair Program Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment In the search for a preventative treatment of skin cancers, including melanoma, it is imperative to understand and treat DNA damage caused by ultraviolet (UV) radiation. Following the treatment of a patient suffering from xeroderma pigmentosum (XP), a disease characterised […]

www.clinuvel.com.

Download PDF

 
 

Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment CLINUVEL PHARMACEUTICALS LTD today announced that the first patient diagnosed with xeroderma pigmentosum (XP-C) has received SCENESSE® (afamelanotide 16mg).1 The Special Access Program of one patient is part of CLINUVEL’s DNA Repair Program. CLINUVEL is evaluating SCENESSE® in a staged clinical program to confirm the drug’s ability to […]

www.clinuvel.com.

Download PDF

 
 

Figure 1: CLINUVEL’s DNA Repair Program aims to confirm that intervention with SCENESSE® causes elimination of DNA damage (photoproducts) and regeneration of DNA. The diagram shows that SCENESSE® has been proven to protect skin from light (photoprotection) and shown to repair DNA damage. Since photoprotection and regeneration are necessary to reduce the risk of skin […]

www.clinuvel.com.

Download PDF

 
 

CLINUVEL progresses innovative DNA Repair Program Drug tested to protect skin and regenerate DNA, firstly in XP patients at 10,000-fold skin cancer risk Figure 1: CLINUVEL’s DNA Repair Program aims to confirm that intervention with SCENESSE® causes elimination of DNA damage (photoproducts) and regeneration of DNA. The diagram shows that SCENESSE® has been proven to […]

www.clinuvel.com.

Download PDF

 
Tuesday, 15 January 2019

CLINUVEL Newsletter - January 2019

15 January 2019 Dear patients, shareholders, friends,I wish you all a year in good physical and spiritual health, and a year in which we anticipate further progress of SCENESSE ® (afamelanotide 16mg)1 and CLINUVEL’s other products …

Download PDF
 
Thursday, 10 January 2019

US FDA sets PDUFA date for SCENESSE®

Melbourne, Australia 10 January 2019 Priority Review granted for innovative drug, PDUFA date 8 July 2019  Executive summary New Drug Application submitted in accordance with section 505(b) of the Federal Food, Drug, and Cosmetic Act, filed in …

Download PDF
 
Wednesday, 19 December 2018

CLINUVEL Vitiligo Communiqué

19 December 2018 As a depigmentation disorder (hypomelanosis), vitiligo is the most well-known of all leucodermatoses (“white skin”) whereby other variants of loss of skin pigmentation – temporary or permanent - are described as albinism, piebaldism, …

Download PDF
 
Monday, 17 December 2018

CLINUVEL Newsletter - December 2018

17 December 2018 As the year draws to a close we look back at a hectic, yet successful, 12 months. In CLINUVEL’s marathon, the past year looked like a series of endless sprints to accomplish all we had …

Download PDF
 
Monday, 05 November 2018

CLINUVEL Newsletter - November 2018

05 November 2018 The most recent quarterly financial results (1 July-30 September 2018) confirm the steady growth in clinical demand for SCENESSE® (afamelanotide 16mg) in erythropoietic protoporphyria (EPP), a rare genetic metabolic disorder.1 EPP is classified …

Download PDF
 
Friday, 05 October 2018

Chair Letter to Shareholders

05 October 2018 This is a thank you to shareholders, investors, patients, clinicians, and all those who have continued to support CLINUVEL together with new shareholders who have recently gained confidence to join the CLINUVEL register. …

Download PDF
 
Friday, 27 July 2018

CLINUVEL Newsletter - July 2018

27 July 2018 On 25 June 2018 CLINUVEL announced its New Drug Application (NDA) for SCENESSE® (afamelanotide 16mg) for adult erythropoietic protoporphyria (EPP) patients had been submitted to the US Food and Drug Administration (FDA). It …

Download PDF
 
Monday, 26 March 2018

CLINUVEL Newsletter - March 2018

26 March 2018 The erythropoietic protoporphyria (EPP) Expert Meeting in Vienna on 16 March has had quite an impact on our global teams working in the fields of photomedicine and melanocortins. The interest in SCENESSE® (afamelanotide …

Download PDF
 
Monday, 12 February 2018

CLINUVEL Newsletter - February 2018

12 February 2018 We started this year with limitless optimism and energy, and I attribute this to a foundation of internal changes made over the past 16 months. Our fascinating journey is marred with frequent need …

Download PDF
 
Wednesday, 10 January 2018

Chair Letter to Shareholders

11 January 2018 Whilst the Board of CLINUVEL looks back on a very successful 2017 it must now look forward to exciting times ahead. The Group will engage in many activities on several continents, and we …

Download PDF